Morepen Laboratories Share Price
Sector: Biotechnology & Drugs
61.98 +3.16 (5.37%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
57.68
Today’s High
64.90
52 Week Low
41.66
52 Week High
100.80
62.05 +3.23 (5.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
57.75
Today’s High
64.90
52 Week Low
42.00
52 Week High
100.90
Key Metrics
- Market Cap (In Cr) 3396.21
- Beta 0.96
- Div. Yield (%) 0
- P/B 3.55
- TTM P/E 32.56
- Peg Ratio -5.58
- Sector P/E 26.62
- Open Price 58.43
- Prev Close 58.82
Morepen Laboratories Analysis
Price Analysis
-
1 Week12.34%
-
3 Months-7.5%
-
6 Month-21.15%
-
YTD-24.74%
-
1 Year17.52%
Risk Meter
- 54% Low risk
- 54% Moderate risk
- 54% Balanced Risk
- 54% High risk
- 54% Extreme risk
Morepen Laboratories News
Intraday stocks for today under ₹100: Experts pick four stocks to buy or sell
2 min read . 21 Mar 2025Stocks to buy under ₹100: Experts recommend three intraday stocks for today
2 min read . 19 Mar 2025Intraday stocks for today: Experts recommend five shares to buy today — 26 Dec
2 min read . 26 Dec 2024Morepen Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1690.43
- Selling/ General/ Admin Expenses Total
- 301.51
- Depreciation/ Amortization
- 33.47
- Other Operating Expenses Total
- 141.58
- Total Operating Expense
- 1565.28
- Operating Income
- 125.16
- Net Income Before Taxes
- 135.42
- Net Income
- 96.16
- Diluted Normalized EPS
- 1.88
- Period
- 2024
- Total Assets
- 1293.21
- Total Liabilities
- 445.98
- Total Equity
- 847.23
- Tangible Book Valueper Share Common Eq
- 14.73
- Period
- 2024
- Cashfrom Operating Activities
- 73.37
- Cashfrom Investing Activities
- -83.3
- Cashfrom Financing Activities
- 5.2
- Net Changein Cash
- -4.72
- Period
- 2023
- Total Revenue
- 1417.53
- Selling/ General/ Admin Expenses Total
- 293.7
- Depreciation/ Amortization
- 27.93
- Other Operating Expenses Total
- 70.86
- Total Operating Expense
- 1365.93
- Operating Income
- 51.6
- Net Income Before Taxes
- 55.76
- Net Income
- 38.68
- Diluted Normalized EPS
- 0.77
- Period
- 2023
- Total Assets
- 1110.5
- Total Liabilities
- 357.59
- Total Equity
- 752.91
- Tangible Book Valueper Share Common Eq
- 12.77
- Period
- 2023
- Cashfrom Operating Activities
- -91.17
- Cashfrom Investing Activities
- -46.51
- Cashfrom Financing Activities
- 143.54
- Net Changein Cash
- 5.86
- Period
- 2022
- Total Revenue
- 1546.83
- Selling/ General/ Admin Expenses Total
- 271.95
- Depreciation/ Amortization
- 27.64
- Other Operating Expenses Total
- 74.26
- Total Operating Expense
- 1437.8
- Operating Income
- 109.03
- Net Income Before Taxes
- 126.7
- Net Income
- 101.68
- Diluted Normalized EPS
- 1.96
- Period
- 2022
- Total Assets
- 1070.05
- Total Liabilities
- 491.49
- Total Equity
- 578.56
- Tangible Book Valueper Share Common Eq
- 9.91
- Period
- 2022
- Cashfrom Operating Activities
- -57.76
- Cashfrom Investing Activities
- -31.68
- Cashfrom Financing Activities
- 63.85
- Net Changein Cash
- -25.58
- Period
- 2021
- Total Revenue
- 1188.06
- Selling/ General/ Admin Expenses Total
- 225.24
- Depreciation/ Amortization
- 30.28
- Other Operating Expenses Total
- 51.88
- Total Operating Expense
- 1099.83
- Operating Income
- 88.23
- Net Income Before Taxes
- 98.51
- Net Income
- 97.09
- Diluted Normalized EPS
- 2.15
- Period
- 2021
- Total Assets
- 858.15
- Total Liabilities
- 433.4
- Total Equity
- 424.75
- Tangible Book Valueper Share Common Eq
- 7.33
- Period
- 2021
- Cashfrom Operating Activities
- 50.83
- Cashfrom Investing Activities
- -70.35
- Cashfrom Financing Activities
- 47.27
- Net Changein Cash
- 27.75
- Period
- 2020
- Total Revenue
- 853.07
- Selling/ General/ Admin Expenses Total
- 188.56
- Depreciation/ Amortization
- 36.91
- Other Operating Expenses Total
- 31.5
- Total Operating Expense
- 821.46
- Operating Income
- 31.61
- Net Income Before Taxes
- 39.11
- Net Income
- 33.58
- Diluted Normalized EPS
- 0.75
- Period
- 2020
- Total Assets
- 663.46
- Total Liabilities
- 379.4
- Total Equity
- 284.06
- Tangible Book Valueper Share Common Eq
- 4.49
- Period
- 2020
- Cashfrom Operating Activities
- 11.02
- Cashfrom Investing Activities
- -12.46
- Cashfrom Financing Activities
- 5.49
- Net Changein Cash
- 4.04
- Period
- 2019
- Total Revenue
- 768.54
- Selling/ General/ Admin Expenses Total
- 168.3
- Depreciation/ Amortization
- 39.9
- Other Operating Expenses Total
- 32.9
- Total Operating Expense
- 740.92
- Operating Income
- 27.61
- Net Income Before Taxes
- 29.18
- Net Income
- 28.85
- Diluted Normalized EPS
- 0.64
- Period
- 2019
- Total Assets
- 615.18
- Total Liabilities
- 362.08
- Total Equity
- 253.09
- Tangible Book Valueper Share Common Eq
- 3.65
- Period
- 2019
- Cashfrom Operating Activities
- 17.37
- Cashfrom Investing Activities
- -13.05
- Cashfrom Financing Activities
- -0.44
- Net Changein Cash
- 3.88
- Period
- 2018
- Total Revenue
- 606.51
- Selling/ General/ Admin Expenses Total
- 140.89
- Depreciation/ Amortization
- 34.32
- Other Operating Expenses Total
- 30.69
- Total Operating Expense
- 576.1
- Operating Income
- 30.41
- Net Income Before Taxes
- 29.77
- Net Income
- 29.59
- Diluted Normalized EPS
- 0.66
- Period
- 2018
- Total Assets
- 585.81
- Total Liabilities
- 359.86
- Total Equity
- 225.94
- Tangible Book Valueper Share Common Eq
- 2.98
- Period
- 2018
- Cashfrom Operating Activities
- 63.41
- Cashfrom Investing Activities
- -26.93
- Cashfrom Financing Activities
- -37.77
- Net Changein Cash
- -1.29
- Period
- 2024-12-31
- Total Revenue
- 452.78
- Selling/ General/ Admin Expenses Total
- 88.91
- Depreciation/ Amortization
- 4.93
- Other Operating Expenses Total
- 37.08
- Total Operating Expense
- 421.57
- Operating Income
- 31.21
- Net Income Before Taxes
- 35.21
- Net Income
- 26.69
- Diluted Normalized EPS
- 0.49
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 437.73
- Selling/ General/ Admin Expenses Total
- 92.06
- Depreciation/ Amortization
- 1.86
- Other Operating Expenses Total
- 31.5
- Total Operating Expense
- 395.51
- Operating Income
- 42.21
- Net Income Before Taxes
- 46.02
- Net Income
- 34.85
- Diluted Normalized EPS
- 0.65
- Period
- 2024-09-30
- Total Assets
- 1562.25
- Total Liabilities
- 451.82
- Total Equity
- 1110.43
- Tangible Book Valueper Share Common Eq
- 18.37
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 12.43
- Cashfrom Investing Activities
- -203.74
- Cashfrom Financing Activities
- 193.91
- Net Changein Cash
- 2.6
- Period
- 2024-06-30
- Total Revenue
- 455.22
- Selling/ General/ Admin Expenses Total
- 92.25
- Depreciation/ Amortization
- 5.73
- Other Operating Expenses Total
- 28.54
- Total Operating Expense
- 409.32
- Operating Income
- 45.89
- Net Income Before Taxes
- 48.17
- Net Income
- 36.17
- Diluted Normalized EPS
- 0.71
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 423.07
- Selling/ General/ Admin Expenses Total
- 64.79
- Depreciation/ Amortization
- 9.62
- Other Operating Expenses Total
- 53.38
- Total Operating Expense
- 384.32
- Operating Income
- 38.76
- Net Income Before Taxes
- 42.2
- Net Income
- 28.28
- Diluted Normalized EPS
- 0.55
- Period
- 2024-03-31
- Total Assets
- 1293.21
- Total Liabilities
- 445.98
- Total Equity
- 847.23
- Tangible Book Valueper Share Common Eq
- 14.73
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 73.37
- Cashfrom Investing Activities
- -83.3
- Cashfrom Financing Activities
- 5.2
- Net Changein Cash
- -4.72
- Period
- 2023-12-31
- Total Revenue
- 444.55
- Selling/ General/ Admin Expenses Total
- 92.71
- Depreciation/ Amortization
- 8.45
- Other Operating Expenses Total
- 29.24
- Total Operating Expense
- 402.43
- Operating Income
- 42.12
- Net Income Before Taxes
- 44.02
- Net Income
- 31.99
- Diluted Normalized EPS
- 0.63
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 421.77
- Selling/ General/ Admin Expenses Total
- 87.78
- Depreciation/ Amortization
- 7.69
- Other Operating Expenses Total
- 27.63
- Total Operating Expense
- 395.87
- Operating Income
- 25.9
- Net Income Before Taxes
- 28.68
- Net Income
- 21.26
- Diluted Normalized EPS
- 0.42
- Period
- 2023-09-30
- Total Assets
- 1193.78
- Total Liabilities
- 404.79
- Total Equity
- 788.99
- Tangible Book Valueper Share Common Eq
- 13.59
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 37.5
- Cashfrom Investing Activities
- -39.56
- Cashfrom Financing Activities
- 3.68
- Net Changein Cash
- 1.62
- Period
- 2023-06-30
- Total Revenue
- 401.04
- Selling/ General/ Admin Expenses Total
- 83.6
- Depreciation/ Amortization
- 7.71
- Other Operating Expenses Total
- 30.26
- Total Operating Expense
- 382.66
- Operating Income
- 18.37
- Net Income Before Taxes
- 20.51
- Net Income
- 14.63
- Diluted Normalized EPS
- 0.29
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 363.69
- Selling/ General/ Admin Expenses Total
- 54.06
- Depreciation/ Amortization
- 6.98
- Other Operating Expenses Total
- 53.66
- Total Operating Expense
- 355.11
- Operating Income
- 8.58
- Net Income Before Taxes
- 11.14
- Net Income
- 8.24
- Diluted Normalized EPS
- 0.17
- Period
- 2023-03-31
- Total Assets
- 1110.5
- Total Liabilities
- 357.59
- Total Equity
- 752.91
- Tangible Book Valueper Share Common Eq
- 12.77
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -91.17
- Cashfrom Investing Activities
- -46.51
- Cashfrom Financing Activities
- 143.54
- Net Changein Cash
- 5.86
- Period
- 2022-12-31
- Total Revenue
- 348.47
- Selling/ General/ Admin Expenses Total
- 71.97
- Depreciation/ Amortization
- 7.19
- Other Operating Expenses Total
- 25.26
- Total Operating Expense
- 335.14
- Operating Income
- 13.33
- Net Income Before Taxes
- 14
- Net Income
- 8.99
- Diluted Normalized EPS
- 0.16
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Morepen Laboratories Technical
Moving Average
SMA
- 5 Day56.77
- 10 Day53.91
- 20 Day51.52
- 50 Day50.66
- 100 Day62.78
- 300 Day68.76
Morepen Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 286.6
- -2
- -0.69
- 571.15
- 257.85
- 3212.64
- Dishman Carbogen Amcis
- 202.9
- -2.25
- -1.1
- 307.8
- 132.75
- 3185.79
- Morepen Laboratories
- 61.98
- 3.16
- 5.37
- 100.8
- 41.66
- 3396.21
- Aarti Drugs
- 354.05
- 3.35
- 0.96
- 634.9
- 312.5
- 3232.8
- Panacea Biotec
- 537.05
- 18.35
- 3.54
- 549.05
- 112.7
- 3289.48
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 22.41
- 2.42
- 12.28
- 24.59
- Dishman Carbogen Amcis
- -
- 0.57
- -0.61
- -1.54
- Morepen Laboratories
- 31.27
- 3.55
- 14.17
- 5.49
- Aarti Drugs
- 18.8
- 2.52
- 20.49
- 8.25
- Panacea Biotec
- -
- 3.79
- 31.02
- 24.87
Morepen Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-Feb-25
- Quarterly Results
- 11-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 21-May-24
- Audited Results
- 31-Jan-24
- Quarterly Results
- 02-Nov-23
- Quarterly Results
- 05-Aug-23
- Quarterly Results
- 16-May-23
- Audited Results
- 13-Feb-23
- Quarterly Results
- 10-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 10-Feb-25
- 17-Jan-25
- EGM
- 28-Sept-24
- 11-Sept-24
- AGM
- 18-Mar-24
- 26-Feb-24
- EGM
- 28-Sept-23
- 05-Sept-23
- AGM
- 05-Mar-22
- 11-Feb-22
- EGM
- 20-May-21
- 28-Apr-21
- EGM



